317 related articles for article (PubMed ID: 12374285)
1. A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: two complementary signals to overcome cross-resistance.
Ng CP; Bonavida B
Adv Cancer Res; 2002; 85():145-74. PubMed ID: 12374285
[TBL] [Abstract][Full Text] [Related]
2. Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis.
Odabaei G; Chatterjee D; Jazirehi AR; Goodglick L; Yeung K; Bonavida B
Adv Cancer Res; 2004; 91():169-200. PubMed ID: 15327891
[TBL] [Abstract][Full Text] [Related]
3. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
Ng CP; Zisman A; Bonavida B
Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140
[TBL] [Abstract][Full Text] [Related]
4. Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes.
Frost P; Caliliw R; Belldegrun A; Bonavida B
Int J Oncol; 2003 Feb; 22(2):431-7. PubMed ID: 12527945
[TBL] [Abstract][Full Text] [Related]
5. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal.
Tsuruo T; Naito M; Tomida A; Fujita N; Mashima T; Sakamoto H; Haga N
Cancer Sci; 2003 Jan; 94(1):15-21. PubMed ID: 12708468
[TBL] [Abstract][Full Text] [Related]
6. Sensitization of immunoresistant prostate carcinoma cell lines to Fas/Fas ligand-mediated killing by cytotoxic lymphocytes: independence of de novo protein synthesis.
Frost PJ; Belldegrun A; Bonavida B
Prostate; 1999 Sep; 41(1):20-30. PubMed ID: 10440872
[TBL] [Abstract][Full Text] [Related]
7. TRAIL receptor signalling and modulation: Are we on the right TRAIL?
Mahalingam D; Szegezdi E; Keane M; de Jong S; Samali A
Cancer Treat Rev; 2009 May; 35(3):280-8. PubMed ID: 19117685
[TBL] [Abstract][Full Text] [Related]
8. Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis.
Uslu R; Borsellino N; Frost P; Gárban H; Ng CP; Mizutani Y; Belldegrun A; Bonavida B
Clin Cancer Res; 1997 Jun; 3(6):963-72. PubMed ID: 9815772
[TBL] [Abstract][Full Text] [Related]
9. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.
Frost PJ; Butterfield LH; Dissette VB; Economou JS; Bonavida B
J Immunol; 2001 Mar; 166(5):3564-73. PubMed ID: 11207317
[TBL] [Abstract][Full Text] [Related]
10. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas.
Herr I; Ucur E; Herzer K; Okouoyo S; Ridder R; Krammer PH; von Knebel Doeberitz M; Debatin KM
Cancer Res; 2003 Jun; 63(12):3112-20. PubMed ID: 12810637
[TBL] [Abstract][Full Text] [Related]
11. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells.
Taniai M; Grambihler A; Higuchi H; Werneburg N; Bronk SF; Farrugia DJ; Kaufmann SH; Gores GJ
Cancer Res; 2004 May; 64(10):3517-24. PubMed ID: 15150106
[TBL] [Abstract][Full Text] [Related]
12. Overcoming drug resistance by enhancing apoptosis of tumor cells.
Giménez-Bonafé P; Tortosa A; Pérez-Tomás R
Curr Cancer Drug Targets; 2009 May; 9(3):320-40. PubMed ID: 19442052
[TBL] [Abstract][Full Text] [Related]
13. Ultraviolet-irradiation-induced apoptosis is mediated via ligand independent activation of tumor necrosis factor receptor 1.
Sheikh MS; Antinore MJ; Huang Y; Fornace AJ
Oncogene; 1998 Nov; 17(20):2555-63. PubMed ID: 9840918
[TBL] [Abstract][Full Text] [Related]
14. How melanoma cells evade trail-induced apoptosis.
Hersey P; Zhang XD
Nat Rev Cancer; 2001 Nov; 1(2):142-50. PubMed ID: 11905805
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
Mühlethaler-Mottet A; Flahaut M; Bourloud KB; Auderset K; Meier R; Joseph JM; Gross N
BMC Cancer; 2006 Aug; 6():214. PubMed ID: 16930472
[TBL] [Abstract][Full Text] [Related]
16. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
17. Development of rituximab-resistant B-NHL clones: an in vitro model for studying tumor resistance to monoclonal antibody-mediated immunotherapy.
Jazirehi AR; Bonavida B
Methods Mol Biol; 2011; 731():407-19. PubMed ID: 21516425
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis-modulating agents in combination with radiotherapy-current status and outlook.
Belka C; Jendrossek V; Pruschy M; Vink S; Verheij M; Budach W
Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):542-54. PubMed ID: 14751526
[TBL] [Abstract][Full Text] [Related]
19. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
[TBL] [Abstract][Full Text] [Related]
20. Mutations in apoptosis genes: a pathogenetic factor for human disease.
Müllauer L; Gruber P; Sebinger D; Buch J; Wohlfart S; Chott A
Mutat Res; 2001 Jul; 488(3):211-31. PubMed ID: 11397650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
